| 【Company Research】Jinxin Fertility (1951 HK) – Core emphasis on provision of high quality medical services |
| 【Company Research】Jinxin Fertility (1951 HK) – Core emphasis on provision of high quality medical services |
| 【Company Research】Excellence Commercial Property (6989 HK) – Asset sale will not affect guidance |
| 【Company Research】I-Mab BioPharma (IMAB US) – Appointment of a globally renowned oncologist to lead the R&D organization |
| 【Company Research】ANE (9956 HK) – Largest express freight network operator in China LTL market |
| 【Sector Research】China Banking Sector – Implications of 5 bps cut on 1-yr LPR |
| 【Company Research】Vesync (2148 HK) – FY22E guidance maintained but we are prudent |
| 【Fixed Income Research】SAKAEI – Saka Energi Coverage Initiation |
| 【Company Research】Airdoc Technology (2251 HK) – Pioneer in AI-based medical imaging industry |
| 【Fixed Income Research】GZRFPR - The tender offer and consent solicitation |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
